+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Liraglutide"

From
Obesity Market Report and Forecast 2025-2034 - Product Thumbnail Image

Obesity Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
From
Peptide Based Metabolic Disorder Therapeutic Market in Saudi Arabia - Product Thumbnail Image

Peptide Based Metabolic Disorder Therapeutic Market in Saudi Arabia

  • Report
  • May 2026
  • 150 Pages
  • Saudi Arabia
From
Peptide Based Metabolic Disorder Therapeutic Market in South Africa - Product Thumbnail Image

Peptide Based Metabolic Disorder Therapeutic Market in South Africa

  • Report
  • May 2026
  • 150 Pages
  • South Africa
From
Peptide Based Metabolic Disorder Therapeutic Market in South Korea - Product Thumbnail Image

Peptide Based Metabolic Disorder Therapeutic Market in South Korea

  • Report
  • May 2026
  • 150 Pages
  • South Korea
From
From
Loading Indicator

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes. Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain. Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more